Meta-analyses have shown that patients with a BRAF V600E mutation, especially in combination with a TERT promoter mutation, have a higher risk of unfavorable clinicopathological parameters such as extrathyroidal tumor spread, lymph node metastasis, and a higher TNM stage [4–7]. This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.